The major causative factor of hepatocellular carcinoma (HCC) is chronic infection with hepatitis C virus (HCV) and hepatitis B virus (HBV) in Japan. Alcohol intake and cigarette smoking have also been implicated in the etiology of HCC. Although the biological mechanisms underlying these factors are not fully understood, one of the proposed mechanisms represents the involvement of oxidative DNA damage which can induce mutations leading to cancer. Chronic hepatic inflammation caused by hepatitis viruses and exposure to alcohol and tobacco stimulate the generation of hepatic reactive oxygen species (ROS) causing oxidative DNA damage.

Among many types of oxidative DNA damage, 8-hydroxy-2-deoxyguanine (8-OHdG) is highly mutagenic because of its propensity to mispair with adenine during DNA replication and to cause ultimately GC to TA transversion. The human 8-oxoguanine glycosylase 1 (hOGG1) gene encoded by the hOGG1 gene

Key words: Carcinoma, Hepatocellular; human 8-oxoguanine glycosylase 1; Polymorphism (Genetics).
located on chromosome 3p25/26 has an activity to remove directly 8-OHdG from DNA as a part of the base excision repair pathway.\textsuperscript{12,13} The Ser326Cys polymorphism in exon 7 of \textit{hOGG1} has been related to glycosylase function and an individual’s ability to repair damaged DNA.\textsuperscript{14,15}

Although recent studies\textsuperscript{16-20} suggested that the low active \textit{hOGG1} allele (326Cys) was positively associated with the risk of several cancers while showing interactions with environmental factors, the association between this polymorphism and HCC has not been examined so far. Therefore, we conducted this case-control study including 209 HCC cases and two different controls (275 hospital controls and 381 patients with chronic liver disease [CLD] without HCC); CLD patients were selected as control subjects because most HCC patients in Japan have preexisting CLD.

**METHODS**

**Subjects**
The details of this study have been described elsewhere.\textsuperscript{21} Briefly, all study subjects were restricted to residents of Saga Prefecture, Japan, who were aged 40 to 79 years. Incident HCC cases (n = 209, participation rate = 92%), who were admitted or outpatients of 2 main hospitals in Saga City (Saga Medical School Hospital and Saga Prefectural Hospital) between April 2001 and March 2004, were recruited as case subjects; 198 cases (95%) had preexisting cirrhosis (n = 167) or chronic hepatitis (n = 31). Hospital controls (n = 275, participation rate = 73%) were first-time visitors at the general outpatient clinic of Saga Medical School Hospital between May 2001 and April 2003; these controls were selected so that the sex and age distribution of them would be similar to that of deaths from liver cancer in Saga Prefecture in 1998.\textsuperscript{21} They had various diseases (n = 190), undiagnosed symptoms (n = 49), or no definite abnormality (n = 36). Patients with CLD (298 patients with chronic hepatitis and 83 patients with cirrhosis, participation rate = 96%) were out- or inpatients of the hospitals same as HCC cases between September 2001 and March 2004; patients with special types of CLD (primary and secondary biliary cirrhosis, autoimmune hepatitis, and liver disease due to parasitosis, congestive heart failure, or metabolic disorders) were excluded. All control subjects had no evidence of HCC.

The study protocol was approved by the ethics committees of the above two hospitals, and written informed consent to the use of their blood and clinical information for this study was obtained from all subjects.

**Interviews**
Research nurses interviewed study subjects on alcohol drinking and smoking habits using a uniform questionnaire. A history of heavy drinking was defined as having imbibed 69 g or more of ethanol per day for 10 or more years. We regarded “never smokers” as individuals who had never smoked or had smoked for less than 1 year, “former smokers” as those who stopped smoking 1 or more years before the interview, and “current smokers” as those who currently smoked or stopped smoking less than 1 year prior to the interview. The cumulative amount of smoking was calculated as pack-years.

**Serologic Tests and Genotyping**
Venous blood was drawn, and plasma samples were tested for hepatitis B surface antigen (HBsAg) by a chemiluminescent immunoassay (CLIA; Dainabot, Tokyo, Japan) and for antibodies to HCV (HCVAb) by a 2nd-generation enzyme immunoassay (Abott HCV EIA II; Dainabot, Tokyo).

DNA was extracted fromuffy coat preparations by using a commercial kit (QIAamp DNA Blood Mini kit; QIAGEN Inc, Tokyo). The \textit{hOGG1} Ser326Cys polymorphism was genotyped

---

**Figure 1.** PCR-CTPP analysis for the \textit{hOGG1} polymorphism at codon 326 in exon 7.

| M | CC | CC | CG | CG | GG | GG |
|---|----|----|----|----|----|----|
| 249 bp | | | | | | |
| 200 bp | | | | | | |

The amplified PCR products are 252 bp for the C allele (326Ser) and 194 bp for the G allele (326Cys).
by a polymerase chain reaction (PCR) with confronting two-pair primers (PCR-CTPP) according to Ito et al. Genomic DNA (10-150 ng) was amplified in a volume of 25 μL with 0.18 mM dNTPs, 12.5 pmol of each primer, 0.5 units of AmpliTaq Gold (Perkin-Elmer Corp., Foster City, CA), and 2.5 μL of 10× PCR buffer including 15 mM MgCl₂. The following 4 primers were used for each reaction: F1 (5'-CAGCCCAGACCCAAGATG-GACTC-3'), R1 (5'-TGGCTCTGAGCATGGCGGGG-3'), F2 (5'-CAGTGCCGACCTGGCGCAATG-3'), and R2 (5'-GGTAGTG-CACAGGGAGGCCACATTG-3'). PCR was conducted as follows: a 10 minute initial denature at 95°C, 30 cycles for 1 minute at 95°C, 1 minute at 64°C, and 1 minute at 72°C, and a 5 minute final extension at 72°C. PCR products were subjected to electrophoresis in 2% agarose gels and were visualized with ethidium bromide staining. The primer pair F1 and R1 produced the C allele (Ser326) band (252 bp), while F2 and R2 produced the G allele (326Cys) band (194 bp) (Figure 1). To validate the results, 10% PCR products were subjected to electrophoresis in 2% agarose gels and were visualized with ethidium bromide staining. The primer pair F1 and R1 produced the C allele (Ser326) band (252 bp), while F2 and R2 produced the G allele (326Cys) band (194 bp) (Figure 1). To validate the results, 10% PCR products were subjected to electrophoresis in 2% agarose gels and were visualized with ethidium bromide staining. The primer pair F1 and R1 produced the C allele (Ser326) band (252 bp), while F2 and R2 produced the G allele (326Cys) band (194 bp) (Figure 1). To validate the results, 10% PCR products were subjected to electrophoresis in 2% agarose gels and were visualized with ethidium bromide staining. The primer pair F1 and R1 produced the C allele (Ser326) band (252 bp), while F2 and R2 produced the G allele (326Cys) band (194 bp) (Figure 1). To validate the results, 10% PCR products were subjected to electrophoresis in 2% agarose gels and were visualized with ethidium bromide staining.

**Statistical Analysis**

Chi square tests were used for unadjusted comparisons based on frequency. The Wilcoxon's rank sum test was conducted to compare the distribution of age. Unconditional logistic regression models were used to estimate crude and adjusted odds ratios (ORs) of HCC and their 95% confidence intervals (CIs) for hOGG1 genotypes by using dummy variables, with adjustment for potential confounders including sex, age category (40-49, 50-59, 60-69, and 70-79 years), heavy drinking history, smoking status (never, former, and current smokers), and HBsAg and HCVAb status. The gene-environment interaction on HCC risk was evaluated by including in the model the product terms of variables of interest (i.e., hOGG1 genotype and heavy drinking history/smoking status), as well as main effects and covariates. Likelihood ratio tests were used to examine the overall statistical significance of a set of interaction terms. Tests of linear trend for hOGG1 genotypes were performed by assigning an ordinal variable to the genotypes in the logistic model. All statistical analyses were performed with the SAS®/PC statistical package (SAS Institute Inc., Cary, NC).

**RESULTS**

Selected characteristics of study subjects are shown in Table 1. As compared with hospital controls, HCC cases showed significantly higher prevalences of older subjects (p < 0.01), HBsAg positives (p < 0.01), HCVAb positives (p < 0.01), males with heavy drinking history (p < 0.01), and male current smokers (p = 0.03). As compared to CLD patients, HCC cases revealed significantly greater proportions of males (p < 0.01), older subjects (p < 0.01), and males with heavy drinking history (p < 0.01).

The frequency of hOGG1 genotype showed no significant difference between HCC cases and either control group (p = 0.10 or 0.23) (Table 1). The genotype distributions for hospital controls and CLD patients were in Hardy-Weinberg equilibrium (p = 0.08 and 0.14, respectively). After adjustment for sex, age, heavy drinking history, smoking, HBsAg, and HCVAb, the ORs (and 95% CIs) for the Ser/Cys, Cys/Cys, and Ser/Cys+Cys/Cys genotypes relative to the Ser/Ser genotype were estimated at 0.79 (0.35-1.79), 0.48 (0.18-1.27), and 0.68 (0.31-1.46) against hospital controls respectively, and at 1.51 (0.96-3.37), 0.86 (0.50-1.47), and 1.25 (0.82-1.91) against CLD patients respectively.

Table 2 shows the adjusted ORs of HCC for hOGG1 genotypes according to heavy drinking history and current smoking status. We could not detect any significant linear trend for the genotypes in any stratum. Among those without heavy drinking history, a significant risk excess for the Ser/Cys vs. Ser/Ser genotype (fully-adjusted OR = 1.82, 95% CI: 1.10-3.01) was observed between HCC cases and CLD patients, yet the risk for the Cys/Cys vs. Ser/Ser genotype was not elevated (OR = 0.90, 95% CI: 0.50-1.64). A similar tendency was observed among those without current smoking. In comparison of HCC cases with hospital controls, additional adjustment for HBsAg and HCVAb substantially altered the OR on some occasions (e.g., OR for Cys/Cys among current smokers), but with a very wide CI. No significant interaction was found between the hOGG1 genotype and either heavy drinking history or current smoking. Although we conducted corresponding analyses based on daily amount of alcohol drinking and pack-years of smoking, the results were essentially identical (data not shown).

**DISCUSSION**

In the present study, we could not find any significant association between hOGG1 Ser326Cys polymorphism and overall HCC risk. In subgroup analyses according to drinking and smoking habits, there was some risk increase for the Ser/Cys vs. Ser/Ser genotype, yet such a finding might be due to chance variation in the light of the absence of risk increase for the Cys/Cys vs. Ser/Ser genotype. In addition, no significant gene-alcohol or gene-smoking interaction was evident.

Chronic inflammation caused by hepatotropic viruses and exposure to alcohol and tobacco stimulate hepatic ROS generation, and some reports also have demonstrated that both HCV and HBV infections could induce ROS without inflammation. Interestingly, a recent clinical study reported that reducing iron, one of the sources of ROS generation, by phlebotomy and low iron diet decreased hepatic levels of 8-OHdG and eventually the risk of HCC development in patients with chronic hepatitis C after 6 years of follow-up. These reports suggest an important role of oxidative stress in hepatocarcinogenesis.

hOGG1, which acts in the DNA base excision repair pathway, excises 8-OHdG resulting from oxidative stress. The Ser326Cys polymorphism in hOGG1 may alter glycosylase function, and some studies showed that hOGG1 protein encoded by the 326Cys...
Table 1. Selected characteristics of study subjects.

| Factor                          | HCC cases | Hospital controls | CLD patients | P  | P† |
|--------------------------------|-----------|-------------------|--------------|----|----|
| Sex                            |           |                   |              |    |    |
| Male                           | 141 (67.5)| 180 (65.5)        | 205 (53.8)   | 0.64 | <0.01 |
| Female                         | 68 (32.5)| 95 (34.5)         | 176 (46.2)   |    |    |
| Age (year)                     |           |                   |              |    |    |
| 40-49                          | 6 (2.9)   | 42 (15.3)         | 73 (19.2)    |    |    |
| 50-59                          | 28 (13.4) | 85 (30.9)         | 93 (24.4)    |    |    |
| 60-69                          | 76 (36.4) | 86 (31.3)         | 136 (35.7)   |    |    |
| 70-79                          | 99 (47.4) | 62 (22.6)         | 79 (9.2)     | <0.01 | <0.01 |
| Median                         | 69 yr     | 61 yr             | 61 yr        | <0.01 | <0.01 |
| HBsAg                          |           |                   |              |    |    |
| Negative                       | 190 (90.9)| 269 (97.8)        | 346 (90.8)   |    |    |
| Positive                       | 19 (9.1)  | 6 (2.2)           | 35 (9.2)     | <0.01 | 0.97 |
| HCVAb                          |           |                   |              |    |    |
| Negative                       | 30 (14.4) | 254 (92.4)        | 54 (14.2)    |    |    |
| Positive                       | 179 (85.7)| 21 (7.6)         | 327 (85.8)   | <0.01 | 0.95 |
| Heavy drinking history (male)  |           |                   |              |    |    |
| No                             | 95 (67.4) | 158 (87.8)        | 170 (82.9)   | <0.01 | <0.01 |
| Yes                            | 46 (32.6) | 22 (12.2)         | 35 (17.1)    |    |    |
| Heavy drinking history (female)|           |                   |              |    |    |
| No                             | 65 (95.6)| 94 (99.0)         | 172 (97.7)   |    |    |
| Yes                            | 3 (4.4)  | 1 (1.1)           | 4 (2.3)      | 0.17 | 0.37 |
| Smoking status (male)          |           |                   |              |    |    |
| Never                          | 24 (17.0) | 50 (27.8)         | 54 (26.3)    |    |    |
| Former                         | 51 (36.2) | 67 (37.2)         | 76 (37.1)    |    |    |
| Current                        | 66 (46.8) | 63 (35.0)         | 75 (36.7)    | 0.03 | 0.07 |
| Smoking status (female)        |           |                   |              |    |    |
| Never                          | 61 (89.7)| 88 (92.6)         | 150 (85.2)   |    |    |
| Former                         | 4 (5.9)  | 3 (3.2)           | 15 (8.5)     |    |    |
| Current                        | 3 (4.4)  | 4 (4.2)           | 11 (6.3)     | 0.70 | 0.66 |
| hOGG1 genotype                 |           |                   |              |    |    |
| Ser/Ser                        | 56 (26.8)| 73 (26.5)         | 105 (27.6)   |    |    |
| Ser/Cys                        | 110 (52.6)| 123 (44.7)        | 176 (46.2)   |    |    |
| Cys/Cys                        | 43 (20.6)| 79 (28.7)         | 100 (26.2)   | 0.10 | 0.23 |

* : Comparisons were made between HCC cases and hospital controls.
† : Comparisons were made between HCC cases and CLD patients.

HCC: hepatocellular carcinoma
CLD: chronic liver diseases
Table 2. Adjusted odds ratios (ORs) and their 95% confidence intervals (CIs) of HCC for *hOGG1* genotypes according to heavy drinking history and current smoking status.

|                  | HCC cases n(%) | Hospital controls n(%) | CLD patients n(%) | HCC cases vs. hospital controls OR* (95% CI) | OR* (95% CI) | HCC cases vs. CLD patients OR (95% CI) | OR (95% CI) |
|------------------|----------------|------------------------|-------------------|--------------------------------------------|--------------|----------------------------------------|------------|
| **Without heavy alcohol drinking history** |                |                        |                   |                                           |              |                                        |            |
| Ser/Ser          | 40 (25.0)      | 64 (25.4)              | 96 (28.1)         | 1.00 (reference)                           | 1.00 (reference) | 1.00 (reference)                           | 1.00 (reference) |
| Ser/Cys          | 88 (55.0)      | 115 (45.6)             | 154 (45.0)        | 1.31 (0.77-2.22)                           | 0.73 (0.28-1.93) | 1.78 (1.07-3.65)                           | 1.82 (1.10-3.01) |
| Cys/Cys          | 32 (20.0)      | 73 (29.0)              | 92 (26.9)         | 0.80 (0.43-1.49)                           | 0.42 (0.13-1.28) | 0.90 (0.50-1.63)                           | 0.90 (0.50-1.64) |
| P for trend      |                |                        |                   |                                           | 0.51          | 0.13                                    | 0.84       |
| **With heavy alcohol drinking history** |                |                        |                   |                                           |              |                                        |            |
| Ser/Ser          | 16 (32.7)      | 9 (39.1)               | 9 (23.1)          | 1.00 (reference)                           | 1.00 (reference) | 1.00 (reference)                           | 1.00 (reference) |
| Ser/Cys          | 22 (44.9)      | 8 (34.8)               | 22 (56.4)         | 1.56 (0.44-5.59)                           | 0.92 (0.17-5.06) | 0.50 (0.16-1.50)                           | 0.63 (0.18-2.19) |
| Cys/Cys          | 11 (22.5)      | 6 (26.1)               | 8 (20.5)          | 1.05 (0.24-4.61)                           | 1.02 (0.10-10.06) | 0.70 (0.18-2.79)                           | 0.84 (0.20-3.84) |
| P for trend      |                |                        |                   |                                           | 0.87          | 0.99                                    | 0.54       |
| P for interaction | 0.94          | 0.95                   |                   |                                           | 0.13          | 0.16                                    |            |
| **Without current smoking** |                |                        |                   |                                           |              |                                        |            |
| Ser/Ser          | 35 (25.0)      | 56 (26.9)              | 78 (26.4)         | 1.00 (reference)                           | 1.00 (reference) | 1.00 (reference)                           | 1.00 (reference) |
| Ser/Cys          | 77 (55.0)      | 91 (43.8)              | 136 (46.1)        | 1.69 (0.95-3.00)                           | 1.00 (0.38-2.59) | 1.61 (0.95-2.72)                           | 1.65 (0.97-2.81) |
| Cys/Cys          | 28 (20.0)      | 61 (29.3)              | 81 (27.5)         | 0.83 (0.42-1.63)                           | 0.60 (0.20-1.84) | 0.82 (0.44-1.53)                           | 0.86 (0.46-1.61) |
| P for trend      |                |                        |                   |                                           | 0.66          | 0.39                                    | 0.61       |
| **With current smoking** |                |                        |                   |                                           |              |                                        |            |
| Ser/Ser          | 21 (30.4)      | 17 (25.4)              | 27 (31.4)         | 1.00 (reference)                           | 1.00 (reference) | 1.00 (reference)                           | 1.00 (reference) |
| Ser/Cys          | 33 (47.8)      | 32 (47.8)              | 40 (46.5)         | 0.77 (0.31-1.92)                           | 0.42 (0.07-2.42) | 1.04 (0.43-2.52)                           | 1.01 (0.41-2.52) |
| Cys/Cys          | 15 (21.7)      | 18 (26.9)              | 19 (22.1)         | 0.81 (0.29-2.32)                           | 0.07 (0.003-1.39) | 1.00 (0.35-2.84)                           | 0.92 (0.32-2.67) |
| P for trend      |                |                        |                   |                                           | 0.69          | 0.08                                    | 0.99       |
| P for interaction | 0.15          | 0.70                   |                   |                                           | 0.52          | 0.69                                    |            |

*: Adjusted for sex, age category (40-49, 50-59, 60-69, and 70-79 years), and either smoking status (never, former, and current smokers) or heavy drinking history.

†: Adjusted for the above factors plus HBsAg and HCVAb.

‡: A "heavy alcohol drinking history" was defined as having imbibed ≥69 g ethanol per day for ≥10 years.

§: Calculated by the likelihood ratio test.

HCC: hepatocellular carcinoma
CLD: chronic liver diseases
had substantially lower DNA repair activity than that encoded by the 326Ser allele in an in vitro Escherichia coli complementation activity assay\(^6\) and in human cells in vivo\(^7\) whereas others did not find such a difference.\(^26\)-\(^27\) Thus, there is limited evidence of the genotype-phenotype relation, yet recent epidemiologic studies suggested that the putative low active allele (326Cys) was positively associated with lung, orolaryngeal, esophageal, stomach, and colon cancers,\(^16\)-\(^20\) but not with breast cancer.\(^28\) To our knowledge, this is the first epidemiologic study on the association between the Ser326Cys polymorphism and HCC risk. Despite its high biological plausibility, however, we could not obtain any significant findings.

In this study, selection bias among controls could be responsible for the lack of association. However, we used two different control groups, and the results based on both control groups showed a similar tendency. Furthermore, the observed frequencies of the 326Ser allele (0.49 among hospital controls and 0.51 among CLD patients) were close to those in two earlier case-control studies among the Japanese (0.53 in both).\(^19\)-\(^22\) Given the sample size and the genotype frequency of hospital controls, we had an 83% chance of detecting a doubling of the risk for Ser/Cys+Cys/Cys (putative risk genotypes) vs. Ser/Ser (two-sided p = 0.05).

The difference of hOGG1 activity potentially caused by the Ser326Cys polymorphism may be compensated by higher induction of other cooperative enzymes (e.g., human MTH homolog \(^1\) or human MutY homolog\(^3\)) that prevent 8-OHdG-induced mutagenesis. In addition, regardless of the polymorphism, hOGG1 activity may be functionally inhibited by increased NO production resulting from chronic inflammation, which usually exists as the background of HCC, since NO mediated inhibition of hOGG1 activity has been shown in cholangiocarcinoma cell line.\(^4\) On the other hand, Sugimura et al.\(^22\) reported that the risk for lung cancer associated with the hOGG1 Cys/Cys genotype differed by histological subtypes, being elevated for squamous cell carcinoma but not for adenocarcinoma. HCC might represent a histological type unrelated to this genotype.

In conclusion, our results suggest that the hOGG1 Ser326Cys polymorphism may not play a major role as an independent factor in hepatocarcinogenesis. Although this case-control study of moderate size is among the largest ones that have been reported on the association between HCC and genetic polymorphisms, we could not exclude the possibility of a weak association (e.g., OR < 2.0) with the hOGG1 polymorphism and its interaction with environmental factors. Further large studies are needed to address these issues.

**ACKNOWLEDGMENTS**

We are grateful to S. Ohtsuka, Y. Fujigami, S. Yamashita, T. Koyanagi, and M. Tanaka for interviewing subjects and blood collection and to K. Takahashi for technical assistance. We also express our deep appreciation to Emeritus Prof. J. Tadano of the Department of Laboratory Medicine, Saga Medical School, and the staff of all the relevant departments for their kind cooperation.

**REFERENCES**

1. Tanaka K, Hirohata T, Koga S, Sugimachi K, Kanematsu T, Ohroyoji F, et al. Hepatitis C and Hepatitis B in the etiology of hepatocellular carcinoma in the Japanese Population. Cancer Res 1991; 51: 2842-7.
2. Tsukuma H, Hiyaama T, Tanaka S, Nakao M, Yabuchii T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
3. Shibata A, Fukuoka K, Nishioryi A, Ogimoto I, Sakata R, Tanikawa K. A case-control study on male hepatocellular carcinoma based on hospital and community controls. J Epidemiol 1998; 8: 1-5.
4. Tanaka K, Hirohata T, Fukuoka K, Shibata A, Tsukuma H, Hiyaama T. Risk factors for hepatocellular carcinoma among Japanese women. Cancer Causes Control 1995; 6: 91-8.
5. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997; 278: 1043-50.
6. Marnett LJ. Oxiradicals and DNA damage. Carcinogenesis 2000; 21: 361-70.
7. Shimoda R, Nagashima M, Sakamoto M, Yamaguchi N, Hirohashi S, Yokota J, et al. Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Cancer Res 1994; 54: 3171-2.
8. Albano E. Free radical mechanisms in immune reactions associated with alcoholic liver disease. Free Radic Biol Med 2002; 32: 110-4.
9. Asami S, Hirano T, Yamaguchi R, Tomioka Y, Itoh H, Kasai H. Increase of a type of oxidative DNA damage, 8-hydroxyguanine, and its repair activity in human leukocytes by cigarette smoking. Cancer Res 1996; 56: 2546-9.
10. Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G----T and A----C substitutions. J Biol Chem 2002; 277: 166-72.
11. Hazra TK, Hill JW, Izumi T, Mitra S. Multiple DNA glycosylases for repair of 8-oxoguanine and their potential in vivo functions. Prog Nucleic Acid Res Mol Biol 2001; 68: 193-205.
12. Boiteux S, Radicella JP. The human OGG1 gene: structure, functions, and its implication in the process of carcinogenesis. Arch Biochem Biophys 2000; 377: 1-8.
13. Sunaga N, Kohno T, Shinmura K, Saitoh T, Matsuda T, Saito R, et al. OGG1 protein suppresses G:C-->T:A mutation in a shuttle vector containing 8-hydroxyguanine in human cells. Carcinogenesis 2001; 22: 1355-62.
14. Kohno T, Shinmura K, Tosaka M, Tani M, Kim SR, Sugimura H, et al. Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of
14. Sakamoto T, Hara M, Higaki Y, Ichiba M, Horita M, Mizuta T, et al. Influence of alcohol consumption and gene polymorphisms of ADH2 and ALDH2 on hepatocellular carcinoma in a Japanese population. Int J Cancer 2006; 118: 1501-7.

15. Yamane A, Kohno T, Ito K, Sunaga N, Aoki K, Yoshimura K, et al. Differential ability of polymorphic OGG1 proteins to suppress mutagenesis induced by 8-hydroxyguanine in human cell in vivo. Carcinogenesis 2004; 25: 1689-94.

16. Park J, Chen L, Tockman MS, Elahi A, Lazarus P. The human 8-oxoguanine DNA N-glycosylase 1 (hOGG1) DNA repair enzyme and its association with lung cancer risk. Pharmacogenetics 2004; 14: 103-9.

17. Elahi A, Zheng Z, Park J, Eyring K, McCaffrey T, Lazarus P. The human OGG1 DNA repair enzyme and its association with oropharyngeal cancer risk. Carcinogenesis 2002; 23: 1229-34.

18. Xing DY, Tan W, Song N, Lin DX. Ser326Cys polymorphism in hOGG1 gene and risk of esophageal cancer in a Chinese population. Int J Cancer 2001; 95: 140-3.

19. Tsukino H, Hanaoka T, Otani T, Iwasaki M, Kobayashi M, Hara M, et al. hOGG1 Ser326Cys polymorphism, interaction with environmental exposures, and gastric cancer risk in Japanese populations. Cancer Sci 2004; 95: 977-83.

20. Kim JI, Park YJ, Kim KH, Kim JL, Song BJ, Lee MS, et al. hOGG1 Ser326Cys polymorphism modifies the significance of the environmental risk factor for colon cancer. World J Gastroenterol 2003; 9: 956-60.

21. Sakamoto T, Hara M, Higaki Y, Ichiba M, Horita M, Mizuta T, et al. Influence of alcohol consumption and gene polymorphisms of ADH2 and ALDH2 on hepatocellular carcinoma in a Japanese population. Int J Cancer 2006; 118: 1501-7.

22. Ito H, Hamajima N, Takezaki T, Matsuo K, Tajima K, Hatoooka S, et al. A limited association of OGG1 Ser326Cys polymorphism for adenocarcinoma of the lung. J Epidemiol 2002; 12: 258-65.

23. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001; 61: 4365-70.

24. Waris G, Siddiqui A. Regulatory mechanisms of viral hepatiti B and C. J Biosci 2003; 28: 311-21.

25. Kato J, Kobune M, Nakamura T, Kuroiwa G, Takada K, Takimoto R, et al. Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 2001; 61: 8697-702.

26. Dherin C, Radicella JP, Dizdaroglu M, Boiteux S. Excision of oxidatively damaged DNA bases by the human alpha-hOGG1 protein and the polymorphic alpha-hOGG1(Ser326Cys) protein which is frequently found in human populations. Nucleic Acids Res 1999; 27: 4001-7.

27. Janssen K, Schlink K, Gotte W, Hippler B, Kaina B, Oesch F. DNA repair activity of 8-oxoguanine DNA glycosylase 1 (OGG1) in human lymphocytes is not dependent on genetic polymorphism Ser326/Cys326. Mutat Res 2001; 486: 207-16.

28. Cai Q, Shu XO, Wen W, Courtney R, Dai Q, Gao YT, Zheng W. Functional Ser326Cys polymorphism in the hOGG1 gene is not associated with breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2006; 15: 403-4.

29. Furuichi M, Yoshida MC, Oda H, Tajiri T, Nakabeppu Y, Tsuzuki T, et al. Genomic structure and chromosome location of the human mutT homologue gene MTH1 encoding 8-oxo-dGTPase for prevention of A:T to C:G transversion. Genomics 1994; 24: 485-90.

30. Slupska MM, Baikalov C, Luther WM, Chiang JW, Wei YF, Miller JH. Cloning and sequencing a human homolog (hMYH) of the Escherichia coli mutY gene whose function is required for the repair of oxidative DNA damage. J Bacteriol 1996; 178: 3885-92.

31. Jaiswal M, LaRusso NF, Nishioka N, Nakabeppu Y, Gores GJ. Human Ogg1, a protein involved in the repair of 8-oxoguanine, is inhibited by nitric oxide. Cancer Res 2001; 61: 6388-93.

32. Sugimura H, Kohno T, Nakabeppu Y, Gores GJ. Human Ogg1, a protein involved in the repair of 8-oxoguanine, is inhibited by nitric oxide. Cancer Res 2001; 61: 6388-93.